Evidence map›Paper›PMID 41544216›Full record

ArticleBlood advances2026

Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT.

Melanie de Gier, Jakov Korzhenevich, Franziska M Schmidt, Iga Janowska, Monique M van Ostaijen-Ten Dam, Ingrid Pico-Knijnenburg, Davy Cats, Franziska Keller, Petra Hadlova, Mirjam Kunze and 7 more

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Melanie de GierLaboratory for Pediatric Immunology, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children's Hospital, Leiden, The Netherlands.ORCID 0000-0003-2868-0127
Jakov KorzhenevichDivision of Clinical and Experimental Immunology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Franziska M SchmidtDivision of Clinical and Experimental Immunology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.ORCID 0009-0004-8266-4042
Iga JanowskaDepartment of Rheumatology and Clinical Immunology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.ORCID 0009-0004-7526-2803
Monique M van Ostaijen-Ten DamLaboratory for Pediatric Immunology, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children's Hospital, Leiden, The Netherlands.ORCID 0000-0001-6772-7456
Ingrid Pico-KnijnenburgLaboratory for Pediatric Immunology, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children's Hospital, Leiden, The Netherlands.
Davy CatsDepartment of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands.
Franziska KellerDivision of Clinical and Experimental Immunology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Petra HadlovaChildhood Leukaemia Investigation Prague-Cytometry, Department of Paediatric Hematology and Oncology, 2nd Medical School, Charles University, Prague 5, Czech Republic.
Mirjam KunzeDepartment of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-4064-5930
Filiz Markfeld-ErolDepartment of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Kilian ReisingDepartment of Orthopedic Surgery and Traumatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-0785-4645
Hailiang MeiDepartment of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands.
Robbert G M BrediusPediatric Stem Cell Transplantation Unit, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children's Hospital, Leiden, The Netherlands.ORCID 0000-0001-8151-1539
Arjan C LankesterPediatric Stem Cell Transplantation Unit, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children's Hospital, Leiden, The Netherlands.
Mirjam van der BurgLaboratory for Pediatric Immunology, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children's Hospital, Leiden, The Netherlands.ORCID 0000-0002-1510-3104
Marta RizziDivision of Clinical and Experimental Immunology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-5153-6089

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractDefects in B-cell reconstitution upon hematopoietic stem cell (HSC) transplant (HSCT) are a common observation, yet the mechanism remains unexplained. The bone marrow (BM) stroma, including mesenchymal stromal cells (MSCs), guides HSC maintenance and B-lymphopoiesis by secreting crucial cytokines. We report acquired, permanent, selective, and complete B-cell deficiency in the context of full donor chimerism in a patient with X-linked lymphoproliferative disease, and aimed to identify the contribution of the BM microenvironment in disrupted B-cell reconstitution after HSCT. We studied longitudinal BM samples from the patient and his identical twin, both of whom underwent HSCT with the same donor with opposite outcomes in B-cell reconstitution. In the BM of the index patient, we observed progressive loss of proliferation of HSCs and a selective block at the pre-BI cell stage. In vitro modeling studies showed limited survival of patient HSCs and a relative accumulation of pre-B cells. Patient-derived MSCs failed to support survival and proliferation of HSCs and B-cell development of healthy HSCs, which was correlated with reduced CXCL12 levels. Using bulk RNA-sequencing of MSCs and in vitro functional studies, we showed global changes in the patients' MSCs, and a progressive loss of CXCL12 expression. Indeed, survival of the patients' HSCs improved upon supplementing the in vitro development culture with CXCL12, suggesting a contribution of defective CXCL12 signaling to the phenotype. In summary, our data show that an acquired defect in the BM-stromal microenvironment and exhaustion of HSCs and committed progenitors may cause a permanent nonpermissive state for normal B-cell development.

Indexed as

B-LymphocytesBone MarrowCellular MicroenvironmentHematopoietic Stem CellsHematopoietic Stem Cell TransplantationStem Cell NicheCell DifferentiationCell ProliferationChemokine CXCL12HumansMaleMesenchymal Stem CellsChemokine CXCL12

Identifiers

PMID41544216
PMCPMC13101697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.